Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database

• DOI: 10.3389/fonc.2022.941079
• Publication Date: 2022-08-19T07:51:26Z
• Authors: Chanjuan Cui; Lei Deng; Wenqing Wang; Xiayang Ren; Yanfeng Wang; Wei Cui
• Keywords: immune checkpoint inhibitors; 03 medical and health sciences; 0302 clinical medicine; Oncology; cancer; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; faers; respiratory system; adverse events; RC254-282; 3. Good health

Background Immune checkpoint inhibitors (ICIs), the treatment of multiple cancer types, can be associated with respiratory system adverse events (AEs). The aim this study is to quantify association AEs and ICIs characterize profiles ICI-related complications from Food Drug Administration Adverse Event Reporting System (FAERS) data. Methods disproportionality AE-related based on FAERS data January 2014 September 2021 was analyzed using reporting odds ratio (ROR) information component (IC) as measures potential risk increase. Results A total 38,415,849 records were involved; among these, 36,923 related after ICI identified. In first 3 months, cumulative proportion 75.40%. Men had a slightly higher frequency than that women (ROR = 1.74, 95% CI: 1.70–1.78). Death cases in ICI-associated other drug-associated 1.40, 1.38–1.41). Anti-programmed cell death 1 (PD-1) drugs anti-programmed ligand (PD-L1) significantly toxicities. However, anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) did not demonstrate an Interstitial lung disease pneumonitis found all eight types ICIs. addition, 7 10 class-specific (lower tract disorders, pleural pulmonary vascular disorders elsewhere classified (NEC), infections, neoplasms, thoracic disorders) signal values IC 025 0.08 2.66. Conclusions Overall, showed high toxicities caused by Early recognition management are vital importance practice. Maximizing benefit while reducing should become priority.